Cyclacel Pharmaceuticals Competitors and Similar CompaniesClear all

Cyclacel Pharmaceuticals's competitors and similar companies include ArQule, Moderna, CNS Healthcare and R-Pharm.

	Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other serious diseases.	ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.	Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.	CNS Healthcare CNS Healthcare (also known as Clinical Neuroscience Solutions) is a clinical trials organization.	R-Pharm R-Pharm is a pharmaceutical company.
Founding Date	Founding Date 1992	Founding Date 1993	Founding Date 2010	Founding Date 1996	Founding Date 2001
Type	Type Public	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Berkeley Heights, US HQ Dundee City, GB	Locations Burlington, US HQ	Locations Cambridge, US HQ Melbourne, AU Paris, FR München, DE Tokyo, JP Seoul, KR Warszawa, PL see more	Locations Orlando, US HQ	Locations Moskva, RU HQ Baku, AZ Illertissen, DE Lawrence Township, US
Employees	Employees 1214% decrease	Employees 3613% increase	Employees 5,8004% increase	Employees 1541% increase	Employees 462
Valuation ($)	Valuation ($) 1.5 m	Valuation ($) 2.4 b	Valuation ($) 21.2 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Net income	Net income ($14.1m) (FY, 2025)	Net income ($15.5m) (FY, 2018)	Net income ($2.8b) (FY, 2025)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised $ 152.2m	Total funding raised N/A	Total funding raised $ 1.8b	Total funding raised N/A	Total funding raised N/A